Predict your next investment

HEALTHCARE | Drug Development
gordagen.com

See what CB Insights has to offer

Total Raised

$5.33M

Deal Terms

1

Gordagen Pharmaceuticals Funding, Gordagen Pharmaceuticals Valuation & Gordagen Pharmaceuticals Revenue

1 Fundings

Gordagen Pharmaceuticals's latest funding round was a Series A for $5.33M on February 5, 2014.

Gordagen Pharmaceuticals's latest post-money valuation is from February 2014.

Sign up for a free trial to see Gordagen Pharmaceuticals's valuations in February 2014 and more.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

2/5/2014

Series A

$5.33M

Undisclosed Investors

$99M

1

Date

2/5/2014

Round

Series A

Amount

$5.33M

Investors

Undisclosed Investors

Valuation

$99M

Revenue

Sources

1

Gordagen Pharmaceuticals Deal Terms

1 Deal Term

Gordagen Pharmaceuticals's deal structure is available for 1 funding round, including their Series A from February 05, 2014.

Round

Series A

Funding Date

$99M

Pre-Money Valuation

$99M

Post-Money Valuation

$99M

Amount Raised

$99M

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

$99M

Board Voting

$99M

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Series A

$99M

$99M

$99M

$99M

$99M

$99M

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.